PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Mol Immunol. Author manuscript; available in PMC Dec 1, 2010.
Published in final edited form as:
PMCID: PMC2834173
NIHMSID: NIHMS147737
Molecular Mechanism Underlying the Suppression of Lipid Oxidation during Endotoxemia
Urmila Maitra, Samantha Baglin, Neeraj Singh, and Liwu Li
Laboratory of innate immunity and inflammation, Department of Biology, Virginia Tech, Blacksburg, VA 24061
*Address correspondence to: Liwu Li, Life Science 1 Building, Washington Street, Department of Biology, Virginia Tech, Blacksburg, VA 24061. Tel: 540-231-1433; Fax: 540-231-4043; lwli/at/vt.edu
Although both inflammatory and metabolic complications occur during sepsis and endotoxemia, relatively few studies have examined the molecular mechanism underlying LPS-modulated metabolic changes during sepsis. In this report, we have demonstrated that LPS suppresses free fatty acid (FFA) oxidation, and consequently contributes to elevated plasma levels of FFA and triglyceride (TG). Furthermore, this process depends upon the interleukin-1 receptor associated kinase 1 (IRAK-1), one of the key TLR4 intracellular signaling kinases. IRAK-1−/− mice fail to exhibit the dramatic rise in plasma FFA and TG levels compared to wild type (WT) mice following lethal LPS injection. Mechanistically, we demonstrated that LPS suppresses FFA oxidation through decreasing the expression levels of key FFA oxidative genes including CPT-1 and MCAD in both liver and kidney tissues of WT but not IRAK-1−/− mice. The expression of CPT-1 and MCAD is controlled by nuclear receptors and co-receptors including PPARα and PGC-1α. We observed that LPS selectively suppresses the levels of PPARα and PGC-1α in tissues from WT, but not IRAK-1−/− mice. Consequently, IRAK-1−/− mice have a higher survival rate following a lethal dose of LPS. Our current study reveals a novel role for IRAK-1 in the metabolic alterations induced by LPS.
Keywords: Lipopolysaccharide, fatty acid oxidation, innate immunity, regulation, metabolism
Sepsis is a complex yet acute syndrome with both inflammatory and metabolic complications. Disseminated bacterial infection releases the endotoxin lipopolysaccharide (LPS) into circulation, which subsequently triggers a cytokine storm responsible for inflammatory tissue damages (Cohen, 2002; Sriskandan and Altmann, 2008). In addition, there is a dramatic rise in the plasma levels of free fatty acids (FFA) and triglyceride (TG) due to enhanced lipolysis and decreased FFA oxidation in tissues including liver, kidney, heart, and skeletal muscle (Johnson et al., 2005; Khovidhunkit et al., 2004; Rosato et al., 1997; Wang and Evans, 1997; Wolfe and Martini, 2000; Zager et al., 2005). Since the oxidation of FFA, rather than glucose, is the most efficient supplier of energy to vital organs, such a metabolic change significantly decreases the energy supply to vital organs (Carre and Singer, 2008; Lind and Lithell, 1994). Collectively, elevated inflammation and reduced energy supply lead to multi-organ failure and death.
Although the molecular signaling processes leading to the induction of inflammatory mediators by LPS is relatively well studied, the mechanism contributing to reduced FFA oxidation is not well understood (Khovidhunkit et al., 2004). Recent studies have revealed that LPS treatment reduces the expression levels of key FFA oxidative enzymes such as carnitine palmitoyltransferase-1 (CPT-1) and medium chain acyl-CoA dehydrogenase (MCAD) in liver, skeletal muscle and kidney tissues (Feingold et al., 2008). The expression of CPT-1 and MCAD is under the control of nuclear receptors including PPARα and PGC-1α (Beigneux et al., 2000; Finck and Kelly, 2006; Kim et al., 2007; Kliewer et al., 2001; Schoonjans et al., 1996). Correspondingly, recent studies also reveal that LPS suppresses the levels of PPARα and PGC-1α in various tissues both in vivo and in vitro (Feingold et al., 2008; Wang et al., 2005).
IRAK-1 is a key intracellular signaling component downstream of TLR4, an LPS receptor (Gottipati et al., 2008; Huang et al., 2004; Li, 2004). A series of studies have revealed that IRAK-1 positively contributes to the activation of NFκB, STAT1/3, and IRF5/7 (Huang et al., 2004; Oganesyan et al., 2006; Uematsu et al., 2005). Consequently, IRAK-1 mediates LPS-induced expression of pro-inflammatory mediators (Deng et al., 2003; Swantek et al., 2000). Additionally, IRAK-1 has been linked to the pathogenesis of sepsis (Arcaroli et al., 2006), in that a genetic variant of the human IRAK-1 gene is associated with an elevated mortality rate in sepsis patients. Despite the prominent role IRAK-1 within the TLR4 signaling pathway, its involvement in LPS-mediated suppression of FFA oxidation has never been defined.
In the current study, we examined the contribution of IRAK-1 to LPS-mediated suppression of FFA oxidation in vivo and in vitro using IRAK-1−/− mice and cells. Furthermore, we studied the effect of LPS on the expression profile of FFA oxidative enzymes in wild type and IRAK-1−/− cells and tissues. Mechanistically, we analyzed the levels of key nuclear receptors such as PPARα and PGC-1α involved in the expression of FFA oxidative genes.
Reagents
LPS (E. Coli O111:B4) was obtained from Sigma. The antibodies against PGC1α, β-actin and PPARα were purchased from Santa Cruz Biotechnology. The primer sets were obtained from IDT.
Mice
Wild-type C57BL/6 mice were obtained from the Charles River Laboratory. IRAK1−/− mice with C57BL/6 background were kindly provided by Dr. James Thomas from the University of Texas Southwestern Medical School. All mice were housed and bred at Derring Hall Animal Facility in compliance with approved Animal Care and Use Committee protocols at Virginia Polytechnic Institute and State University. Wild type and IRAK-1−/− mice of matched gender and age were injected with LPS (E. Coli O111:B4, Sigma) (25mg/kg body weight) or PBS intraperitoneally. Total blood was drawn 16 hours after the injection and plasma was collected for downstream analysis. Liver and kidney tissues were harvested and used for described assays.
Mouse survival study
WT and IRAK-1−/− mice (n=14 per genotype) were injected with LPS (25mg/kg body weight) or PBS intraperitoneally. Injected mice were provided with drinking water only, and closely monitored at 2 hr intervals. Survival and mortality were recorded for a period lasting for 50 hrs.
Western blot analysis
Isolation of whole cell lysates was performed using the T-PER Tissue protein extraction reagent (Thermo Scientific) according to the manufacturer’s protocol. Briefly, the tissue samples (kidney and liver) were weighed and homogenized using the T-PER reagent containing protease inhibitors. The samples were centrifuged at 10,000 × g for 5 min to pellet tissue debris. The supernatant was collected and stored at −80° C for downstream analysis. Western blotting analysis of the protein samples were performed as described previously. Immunoblots were developed using the Amersham ECL Plus chemiluminescent detection system (GE Healthcare). The intensities of the bands were quantified using the Fujifilm Multi Gauge software, and then normalized against β-actin levels.
Real time RT-PCR
Total RNA was prepared from small sections of mouse liver and kidney (50–100µg) using TRIzol (Invitrogen) according to the manufacturer’s protocol. Reverse transcription was carried out using the High-Capacity cDNA Reverse transcription kit (Applied Biosystems) and subsequent real-time RT-PCR analyses were performed using the SYBR green supermix on an IQ5 thermocycler (Biorad). The relative levels of transcripts were calculated using the comparative ΔΔCt method after normalizing with GAPDH levels as the internal control.
Free fatty acid (FFA) and triglyceride (TG) Assay
The levels of free fatty acids were measured in the plasma using the BioVision Free fatty acid colorimetric quantification kit according to the manufacturer’s recommendation. Briefly, 7 µl of sample was measured against a standard of varying concentrations of palmitic acid (provided by the kit) and the O.D. was measured at 570 nm in a 96-well microplate reader (Molecular Devices). Plasma triglyceride levels were quantified using the Wako triglyceride colorimetric assay kit using 2 µl sample per well and a triglyceride standard provided by the kit. . The samples were incubated for 5 min at 37°C and measured on a microplate reader at 600 nm absorbance. Quantification was based on a standard curve derived by linear dilution of the standards included in the respective kits. The levels of both free fatty acid and triglyceride samples were calculated using the slope of the standard curve and the concentration was expressed as nmol/µl.
Statistical analyses
The results are expressed as means +/− standard deviations (SD). Statistical significance was determined using the unpaired 2-tailed Student’s t-test. P-values less than 0.05 were considered statistically significant.
IRAK-1−/− mice have a higher survival rate following lethal LPS challenge
To determine the effect of IRAK-1 in the host response to disseminated endotoxin challenge, we injected either PBS or a lethal dose of LPS (25mg/kg body weight) intraperitoneally into WT and IRAK1−/− mice. The mice were monitored on an hourly basis and their survival times were recorded. As shown in Fig. 1, LPS injection caused significant mortality in the WT mice, with 90% of the mice succumbing over the 50 hour time period. In contrast the mortality rate of IRAK-1−/− was significantly lower, with only a 50% mortality rate during the same observation period. The differences in mortality between the WT and IRAK-1−/− groups were compared using the log rank test, which showed a statistically significant difference (p=0.018) at 50 h endpoint. This is consistent with a previous study demonstrating a higher survival rate in IRAK-1−/− mice following lethal LPS challenge (Swantek et al., 2000).
Fig. 1
Fig. 1
Loss of IRAK-1 protects against LPS-induced endotoxemia
Lethal LPS injection causes dramatic elevation of plasma FFA and TG levels in WT, but not IRAK-1−/− mice
Elevated plasma levels of FFA and TG are hallmarks of endotoxemia and sepsis, due to elevated lipolysis and decreased FFA oxidation and utilization in vital organs and tissues (Khovidhunkit et al., 2004; Wolfe and Martini, 2000; Zager et al., 2005). Since IRAK-1−/− mice display significantly higher survival rate following lethal LPS injection, we subsequently examined the plasma levels of FFA and TG in WT and IRAK-1−/− mice. As shown in Fig. 2, 16 hrs post LPS injection, the plasma levels of FFA and TG were significantly higher in WT mice, changing from 0.2+/−0.052 to 0.5+/−0.091 for FFA and from 0.4+/−0.086 to 0.8+/−0.19 for TG. On the contrary, LPS injection failed to significantly alter the plasma levels of FFA and TG in IRAK-1−/− mice.
Fig. 2
Fig. 2
Increased plasma FFA and TG levels in WT compared to IRAK-1−/− mice in response to LPS
LPS treatment decreases the expression of lipid oxidative genes in WT but not in IRAK1−/− mice
To further elucidate the mechanism underlying IRAK-1 mediated lipid metabolism, we examined the expression levels of several key FFA oxidative genes in WT and IRAK1−/− mice following lethal LPS injection. CPT-1 is necessary for transporting FFA across the mitochondrial membrane for subsequent breakdown and generation of energy in the mitochondria. MCAD is a key enzyme responsible for the first step of β-oxidation and break-down of FFA carbon chains. As shown in Fig. 3A and B, lethal LPS challenge led to a significant decrease in the expression levels of CPT1α and MCAD in WT liver tissues. Likewise, LPS injection also caused significant decrease in the levels of CPT1β and MCAD in the kidney tissues from WT mice (Fig. 3C and D). In contrast, LPS failed to alter the levels of CPT-1 or MCAD in the liver and kidney tissues harvested from IRAK-1−/− mice.
Fig. 3
Fig. 3
Differential effect of LPS on fatty acid oxidation genes in WT and IRAK1−/− mice
LPS treatment reduces the protein levels of PPARα and PGC1α in WT but not in IRAK1−/− mice
Since the expression of CPT-1 and MCAD is known to be controlled by PPARα (Kliewer et al., 2001; Schoonjans et al., 1996), we then examined the effect of LPS on the levels of PPAR in WT and IRAK-1−/− mice. As shown in Fig. 4, LPS injection significantly reduced the levels of PPARα in both liver and kidney tissues from WT mice (an 80% reduction in the liver and a 70% reduction in the kidney compared to the tissues from PBS injected control mice). In contrast, the PPARα levels were not altered by LPS in either liver or kidney tissues harvested from IRAK-1−/− mice.
Fig. 4
Fig. 4
Fig. 4
Effect of LPS on PPARα and PGC1α protein levels in WT and IRAK1−/− mice
In addition to PPARα, several co-activators such as PGC-1α also play a critical role in mediating the expression of genes responsible for FFA oxidation (Finck and Kelly, 2006). Earlier studies have indicated that LPS treatment also reduces the expression levels of PGC1α (Feingold et al., 2008; Kim et al., 2007). Therefore, we examined the levels of PGC1α in the liver extracts of WT and IRAK1−/− mice after LPS administration. Similarly, the protein levels of PGC1α were significantly reduced in the liver tissues of WT mice following LPS injection (an 85% reduction compared to the PBS injected control mice). Instead, the levels of PGC-1α remained steady in liver tissues collected from IRAK1−/− mice treated with either PBS or LPS.
We have demonstrated that IRAK-1 plays a critical role in LPS-modulated FFA oxidation during endotoxemia. IRAK-1−/− mice do not exhibit the dramatic alteration in plasma levels of FFA and TG, and have improved survival rates following a lethal LPS challenge. Mechanistically, IRAK-1 participates in LPS-mediated suppression of key FFA oxidative genes including CPT1 and MCAD, via suppressing the transcription factors PPARα and PGC-1α.
Our finding confirms and extends previous studies demonstrating the suppressive effect of LPS on FFA oxidation (Feingold et al., 2008; Khovidhunkit et al., 2004). The reduced expression of key FFA oxidative genes due to the LPS challenge is most likely responsible for this effect (Feingold et al., 2008). LPS exerts its pleiotropic effects through TLR4 and multiple downstream intracellular adaptor molecules as well as effector kinases (Su, 2005). Given the fact that multiple pathways diverge downstream of the LPS receptor TLR4, it is likely that selected intracellular molecules may be specifically involved in suppressing the expression of FFA oxidative genes. Our current study is the first to provide solid evidence that defines IRAK-1 as a key intracellular signaling molecule involved in the suppression of FFA oxidative genes.
Mechanistically, our data reveals that IRAK-1 is required for LPS-mediated suppression of nuclear receptors (PPARα and PGC-1α), necessary for the active expression of CPT-1 and MCAD (Figure 5). However, the means by which IRAK-1 related downstream signaling processes lead to reduced levels of PPARα and PGC-1α remains unknown. Several potential possibilities for the reduced levels of these nuclear receptors, including reduced transcription and/or translation, and elevated protein degradation, may be involved (Blanquart et al., 2003; Blanquart et al., 2004). In particular, ubiquitin-mediated degradation of PPAR has been previously reported (Blanquart et al., 2002). Moreover, IRAK-1 and its associated molecules such as TRAF6 and Tollip are known to be involved in protein ubiquitination and degradation (Brissoni et al., 2006; Conze et al., 2008; Didierlaurent et al., 2006). Further biochemical analyses using cultured cell lines are warranted to test whether LPS may trigger degradation of PPARα and/or PGC-1α via a pathway involving IRAK-1.
Fig. 5
Fig. 5
A schematic illustration of LPS-mediated regulation of FFA oxidation
This study provides a potential therapeutic target for the development of anti-septic therapies. There is currently no effective drug available to treat sepsis, due to the complex inflammatory and metabolic complications involved in this syndrome. Antibiotics, fluid therapy, and corticosteroids remain the mainstay of sepsis treatment, but these administrations remain supportive at best. Additionally, therapies solely targeting inflammatory cytokines such as TNFα or IL-1β have all failed clinical testing in the past (Abraham et al., 1998; Abraham et al., 1995; Goode et al., 2006). It is likely that interventions in both inflammatory and metabolic alterations are necessary in the prevention of devastating multi-organ failure that ensues following severe disseminated endotoxemia. Thus, compounds that could potentially inactivate IRAK-1, combined with anti-inflammatory agents, may be useful in treating sepsis.
ACKNOWLEDGMENT
This work is partially supported by NIH grants AI50089 and AI64414.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, et al. NORASEPT II Study Group. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351:929–933. [PubMed]
  • Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al. TNF-alpha MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995;273:934–941. [PubMed]
  • Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, Abraham E. Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med. 2006;173:1335–1341. [PMC free article] [PubMed]
  • Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem. 2000;275:16390–16399. [PubMed]
  • Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem. 2002;277:37254–37259. [PubMed]
  • Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol. 2003;85:267–273. [PubMed]
  • Blanquart C, Mansouri R, Fruchart JC, Staels B, Glineur C. Different ways to regulate the PPARalpha stability. Biochem Biophys Res Commun. 2004;319:663–670. [PubMed]
  • Brissoni B, Agostini L, Kropf M, Martinon F, Swoboda V, Lippens S, Everett H, Aebi N, Janssens S, Meylan E, et al. Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr Biol. 2006;16:2265–2270. [PubMed]
  • Carre JE, Singer M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta. 2008;1777:763–771. [PubMed]
  • Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885–891. [PubMed]
  • Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol. 2008;28:3538–3547. [PMC free article] [PubMed]
  • Deng C, Radu C, Diab A, Tsen MF, Hussain R, Cowdery JS, Racke MK, Thomas JA. IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J Immunol. 2003;170:2833–2842. [PubMed]
  • Didierlaurent A, Brissoni B, Velin D, Aebi N, Tardivel A, Kaslin E, Sirard JC, Angelov G, Tschopp J, Burns K. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol Cell Biol. 2006;26:735–742. [PMC free article] [PubMed]
  • Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res. 2008;49:2179–2187. [PMC free article] [PubMed]
  • Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615–622. [PMC free article] [PubMed]
  • Goode S, Tierney G, Deighton C. Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy. Gut. 2006;55:590–591. [PMC free article] [PubMed]
  • Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal. 2008;20:269–276. [PubMed]
  • Huang Y, Li T, Sane DC, Li L. IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem. 2004;279:51697–51703. [PubMed]
  • Hulver MW, Berggren JR, Carper MJ, Miyazaki M, Ntambi JM, Hoffman EP, Thyfault JP, Stevens R, Dohm GL, Houmard JA, et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab. 2005;2:251–261. [PubMed]
  • Johnson AC, Stahl A, Zager RA. Triglyceride accumulation in injured renal tubular cells: alterations in both synthetic and catabolic pathways. Kidney Int. 2005;67:2196–2209. [PubMed]
  • Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–1196. [PubMed]
  • Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism. 2007;56:267–279. [PMC free article] [PubMed]
  • Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001;56:239–263. [PubMed]
  • Li L. Regulation of innate immunity signaling and its connection with human diseases. Curr Drug Targets Inflamm Allergy. 2004;3:81–86. [PubMed]
  • Lind L, Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intensive Care. 1994;5:100–105. [PubMed]
  • Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, Perry A, Cheng G. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature. 2006;439:208–211. [PubMed]
  • Rosato EF, Vemulapalli P, Lang CH, Lanza-Jacoby S. Insulin stimulates lipoprotein lipase activity and synthesis in adipocytes from septic rats. J Surg Res. 1997;73:73–79. [PubMed]
  • Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907–925. [PubMed]
  • Sriskandan S, Altmann DM. The immunology of sepsis. J Pathol. 2008;214:211–223. [PubMed]
  • Su B. Linking stress to immunity? Nat Immunol. 2005;6:541–542. [PubMed]
  • Swantek JL, Tsen MF, Cobb MH, Thomas JA. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J Immunol. 2000;164:4301–4306. [PubMed]
  • Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med. 2005;201:915–923. [PMC free article] [PubMed]
  • Wang X, Evans RD. Effect of endotoxin and platelet-activating factor on lipid oxidation in the rat heart. J Mol Cell Cardiol. 1997;29:1915–1926. [PubMed]
  • Wang Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J Lipid Res. 2005;46:2377–2387. [PubMed]
  • Wolfe RR, Martini WZ. Changes in intermediary metabolism in severe surgical illness. World J Surg. 2000;24:639–647. [PubMed]
  • Zager RA, Johnson AC, Hanson SY. Renal tubular triglyercide accumulation following endotoxic, toxic, and ischemic injury. Kidney Int. 2005;67:111–121. [PubMed]